Avidity Biosciences Reports Third Quarter 2024 Financial Results …

Nov 7, 2024 · These expenses were $77.2 million for the third quarter of 2024 compared with $47.7 million for the third quarter of 2023, and $208.0 million for the first nine months of 2024 …

CouponFollow Extension

$77
OFF

Avidity Biosciences Reports Third Quarter 2024 Financial Results …

1 week from now

Nov 7, 2024 · These expenses were $77.2 million for the third quarter of 2024 compared with $47.7 million for the third quarter of 2023, and $208.0 million for the first nine months of 2024 …

prnewswire.com

$23
OFF

Avidity Biosciences Reports Third Quarter 2024 Financial Results …

1 week from now

Nov 7, 2024 · These expenses were $23.3 million for the third quarter of 2024 compared with $13.7 million for the third quarter of 2023, and $57.9 million for the first nine months of 2024 …

nasdaq.com

17%
OFF

Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats …

1 week from now

Nov 9, 2024 · Avidity Biosciences Third Quarter 2024 ResultsKey Financial Results. Revenue: US$2.34m (down 17% from 3Q 2023). Net loss: US$80.4m (loss widened by 54% from 3Q …

yahoo.com

$2
OFF

Avidity Biosciences Unveils Q3 2024 Financial Progress And …

1 week from now

Nov 7, 2024 · Financial Results for Q3 2024. Looking at their financials, Avidity Biosciences recorded collaboration revenue of $2.3 million for the third quarter of 2024, primarily stemming …

investorshangout.com

$77
OFF

Avidity Biosciences Reports Strong Q3 Progress And Outlook

1 week from now

Nov 8, 2024 · Financially, the company saw an increase in research and development expenses, which rose to $77.2 million in Q3 2024 from $47.7 million in Q3 2023, reflecting the …

businessinsider.com

$66
OFF

Avidity Biosciences Reports First Quarter 2024 Financial Results …

1 week from now

May 9, 2024 · These expenses were $66.8 million for the first quarter of 2024 compared with $47.8 million for the first quarter of 2023. The increases were primarily driven by the …

prnewswire.com

0%
OFF

Avidity Biosciences (NASDAQ:RNA) Hits New 52-Week High

1 week from now

4 days ago · Hedge Funds Weigh In On Avidity Biosciences. Hedge funds have recently modified their holdings of the stock. Nwam LLC boosted its position in Avidity Biosciences by 24.0% in …

marketbeat.com

25%
OFF

Akoya Biosciences Reports Third Quarter 2024 Financial Results

1 week from now

Sep 30, 2024 · Third Quarter 2024 Financial Results For the third quarter of 2024, revenue was $18.8 million , a 25% year-over-year decrease from $25.2 million in the third quarter of 2023.

nasdaq.com

FAQs about Avidity Biosciences Reports Third Quarter 2024 Financial Results … Coupon?

What did avidity Biosciences do in Q3 2024?

SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate progress. ...

How did avidity perform in Q3 2024?

Avidity reported a strong cash position of approximately $1.6 billion, bolstered by a successful public offering. Financially, the company saw an increase in research and development expenses, which rose to $77.2 million in Q3 2024 from $47.7 million in Q3 2023, reflecting the advancement of its key programs. ...

What did avidity Biosciences report in the third-quarter earnings report?

In its third-quarter earnings report for 2024, Avidity Biosciences highlighted significant progress in its clinical trials, including positive data from the Phase 1/2 EXPLORE44 trial for Duchenne muscular dystrophy and the initiation of the biomarker cohort in the FORTITUDE trial for facioscapulohumeral muscular dystrophy. ...

Who is avidity Biosciences?

Avidity Biosciences, Inc., a biopharmaceutical company based in San Diego, specializes in developing RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs) to treat rare muscle diseases such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. ...

What did Aura Biosciences do in the third quarter 2024?

BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the third quarter ended September 30, 2024, and provided recent business highlights. ...